QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NYSE:ANVS

Annovis Bio - ANVS Stock Forecast, Price & News

$15.25
+1.55 (+11.31%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.70
$16.81
50-Day Range
$10.99
$13.70
52-Week Range
$8.39
$23.91
Volume
156,892 shs
Average Volume
38,672 shs
Market Capitalization
$124.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Annovis Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.3% Upside
$40.00 Price Target
Short Interest
Healthy
3.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Annovis Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.97) to ($2.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

782nd out of 1,055 stocks

Pharmaceutical Preparations Industry

389th out of 519 stocks


ANVS stock logo

About Annovis Bio (NYSE:ANVS) Stock

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

ANVS Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Annovis Bio, Inc. (ANVS)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Annovis Bio Continues Gains With 29% Increase
Annovis Bio reports Q1 results
See More Headlines
Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

ANVS Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
3/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+162.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.49 per share

Miscellaneous

Free Float
4,939,000
Market Cap
$124.50 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Dr. Maria L. Maccecchini Ph.D. (Age 71)
    Founder, CEO, Pres & Exec. Director
    Comp: $791.6k
  • Mr. Henry Hagopian III (Age 54)
    M.B.A., Chief Financial Officer
  • Dr. Cheng Fang Ph.D.
    Sr. VP of R&D
  • Ms. Eve M. Damiano M.S.
    RAC, Sr. VP of Regulatory Operations













ANVS Stock - Frequently Asked Questions

Should I buy or sell Annovis Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANVS shares.
View ANVS analyst ratings
or view top-rated stocks.

What is Annovis Bio's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price targets for Annovis Bio's shares. Their ANVS share price forecasts range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for ANVS
or view top-rated stocks among Wall Street analysts.

How have ANVS shares performed in 2023?

Annovis Bio's stock was trading at $13.43 at the start of the year. Since then, ANVS stock has increased by 2.0% and is now trading at $13.70.
View the best growth stocks for 2023 here
.

Are investors shorting Annovis Bio?

Annovis Bio saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 198,300 shares, an increase of 21.9% from the December 15th total of 162,700 shares. Based on an average daily volume of 31,400 shares, the short-interest ratio is currently 6.3 days. Currently, 3.5% of the shares of the company are short sold.
View Annovis Bio's Short Interest
.

When is Annovis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our ANVS earnings forecast
.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.24.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Annovis Bio IPO?

(ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

What is Annovis Bio's stock symbol?

Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."

Who are Annovis Bio's major shareholders?

Annovis Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Merit Financial Group LLC (0.53%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy.
View institutional ownership trends
.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annovis Bio's stock price today?

One share of ANVS stock can currently be purchased for approximately $13.70.

How much money does Annovis Bio make?

Annovis Bio (NYSE:ANVS) has a market capitalization of $111.79 million. The company earns $-14,490,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

How can I contact Annovis Bio?

Annovis Bio's mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The official website for the company is www.annovisbio.com. The company can be reached via phone at 610-727-3913 or via email at joeh@gregoryfca.com.

This page (NYSE:ANVS) was last updated on 1/27/2023 by MarketBeat.com Staff